Clinical Trial

Daratumumab for Patients With Light Chain Amyloidosis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 19, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-center study exploratory clinical trial, aim to exploring the efficacy and safety of daratumumab in patients with AL amyloidosis, patients were divided into three groups: one group received long-term treatment with daratumumab based regimen, and the other group received autologous stem cell transplantation after two standard treatment courses with daratumumab based regimen, and the third group consists of newly diagnosed stage IIIb AL amyloidosis patients who plan to receive DPD treatment. The purpose of this study is to observe the efficacy and safety of Daratumumab, in the treatment of newly diagnosed systemic AL amyloidosis.
Trial Details
NCT Number NCT06376214
Lead Sponsor Nanjing University School of Medicine
Conditions Light Chain (AL) Amyloidosis
Enrollment 100 participants
Start Date 2023-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-19